Read by QxMD icon Read

Drug Metabolism and Personalized Therapy

Ana M Peiró, César Margargit, Adrián LLerena
No abstract text is available yet for this article.
January 6, 2018: Drug Metabolism and Personalized Therapy
Ursula Amstutz, Vid Mlakar, Patricia Huezo-Diaz Curtis, Caroline Samer, Pierre Baumann, Roland P Bühlmann, Peter Meier-Abt, Urs A Meyer, Ron H N van Schaik, Marc Ansari
No abstract text is available yet for this article.
December 21, 2017: Drug Metabolism and Personalized Therapy
Heike Jahnke
No abstract text is available yet for this article.
December 19, 2017: Drug Metabolism and Personalized Therapy
Carlos A Castro-Rojas, Antonio R Esparza-Mota, Francisco Hernandez-Cabrera, Viktor J Romero-Diaz, Juan F Gonzalez-Guerrero, Hector Maldonado-Garza, Irma S Garcia-Gonzalez, Sergio Buenaventura-Cisneros, Josefina Y Sanchez-Lopez, Rocio Ortiz-Lopez, Alberto Camacho-Morales, Oralia Barboza-Quintana, Augusto Rojas-Martinez
BACKGROUND: Fluoropyrimidines form the chemotherapy backbone of advanced and metastatic colorectal cancer (CRC). These drugs are frequently associated with toxicity events that result in dose adjustments and even suspension of the treatment. The thymidylate synthase (TYMS) gene is a potential marker of response and toxicity to fluoropyirimidines as this enzyme is the molecular target of these drugs. Our aim was to assess the association between variants of TYMS with response and toxicity to fluoropyrimidines in patients with CRC in independent retrospective and prospective studies...
December 19, 2017: Drug Metabolism and Personalized Therapy
Jaroslav A Hubacek, Vera Adamkova, Lukas Zlatohlavek, Lenka Steiner-Mrazova, Michal Vrablik
BACKGROUND: The gene COQ2, encoding 4-hydroxybenzoate-polyprenyltransferase (coenzyme Q2), belongs to the candidates potentially influencing statin treatment tolerability. This enzyme is involved in the biosynthesis of coenzyme Q10 (CoQ10), in which depletion induced by statin treatment is implicated in the development of statin-associated muscle symptoms (SAMS). Thus, polymorphisms in the COQ2 gene might explain susceptibility to SAMS. METHODS: Adult patients with SAMS (on low doses of atorvastatin and simvastatin)-induced myalgia/myopathy (n=278), patients on statins but without SAMS (n=293) and population (part of the post-MONICA [Multinational MONItoring of trends and determinants in CArdiovascular disease] study) controls (n=561) were genotyped (polymerase chain reaction-restriction fragment length polymorphism [PCR-RFLP] assay) for rs6535454 and rs4693075 polymorphisms within the COQ2 gene loci...
December 19, 2017: Drug Metabolism and Personalized Therapy
Georgia Ragia, Ioanna-Maria Karantza, Eleni Kelli-Kota, Vana Kolovou, Genovefa Kolovou, Stavros Konstantinides, Efstratios Maltezos, Anna Tavridou, Dimitrios Tziakas, Anke H Maitland-van der Zee, Vangelis G Manolopoulos
BACKGROUND: We have earlier developed a pharmacogenomic algorithm for acenocoumarol dose prediction in Greek patients that included CYP2C9/VKORC1 genetic information. This study aims at analyzing the potential effect of CYP4F2, CYP2C19, and CYP1A2 gene polymorphisms on acenocoumarol dose requirements and at further improving the Greek-specific pharmacogenomic algorithm. METHODS: A total of 205 Greek patients taking acenocoumarol (140 who reached and 65 who did not reach stable dose), participants of acenocoumarol EU-PACT trial, were included in the study...
December 19, 2017: Drug Metabolism and Personalized Therapy
Ken-Ichi Umehara, Felix Huth, Helen Gu, Hilmar Schiller, Tycho Heimbach, Handan He
BACKGROUND: For estimation of fractions metabolized (fm) by different hepatic recombinant human CYP enzymes (rhCYP), calculation of inter-system extrapolation factors (ISEFs) has been proposed. METHODS: ISEF values for CYP1A2, CYP2C19 and CYP3A4/5 were measured. A CYP2C9 ISEF was taken from a previous report. Using a set of compounds, fractions metabolized by CYP enzymes (fm,CYP) values calculated with the ISEFs based on rhCYP data were compared with those from the chemical inhibition data...
November 27, 2017: Drug Metabolism and Personalized Therapy
Carlos L Pérez, Maria T Donato, Ivones Hernández, Miriam T Paz Lopes, Evangelina Marrero, Jose A Herrera, Maria J Gómez-Lechón, Idania Rodeiro
BACKGROUND: The aqueous extract of the Allophylus cominia (L) Sw (Sapindaceae) leaves has shown anti-diabetic, anti-obesity and anti-inflammatory properties. In the Caribbean region, it is typically used for the treatment of type-2 diabetes. METHODS: Considering the herb-drug interaction, the aim of this study was to evaluate the potential effects of the A. cominia extract on the cytochrome P450 (CYP) (rat hepatocyte model) and P-glycoprotein (P-gp) (4T1 cell line) systems...
November 25, 2017: Drug Metabolism and Personalized Therapy
Harminder Singh, Baltej Singh
BACKGROUND: The objective of this study was to evaluate the occurrence of drug-drug interactions (DDIs) in patients on cancer chemotherapy, with the identification of risk factors for these DDIs. METHODS: This was a cross-sectional, descriptive study carried out at the Department of Onco-Radiation at Guru Gobind Singh Medical College, Faridkot, Punjab. The DDIs were recorded with the help of a drug interaction/interplay information software. RESULTS: In total, 354 interactions were identified from 283 patient records...
November 14, 2017: Drug Metabolism and Personalized Therapy
Bardia Jamali, Behjat Sheikholeslami, Yalda Hosseinzadeh Ardakani, Hoda Lavasani, Mohammad-Reza Rouini
BACKGROUND: Tramadol is prone to be abused alone, or in combination with 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy). It was reported that 95% of people with a history of substance abuse in the United States used tramadol in 2004. According to the WHO report in 2016, there was a growing number of tramadol abusers alone or in combination with psychoactive substances such as MDMA in particular in some Middle East countries. Higher concentrations of tramadol in plasma may lead to adverse drug reactions or lethal intoxication...
September 26, 2017: Drug Metabolism and Personalized Therapy
Janthima Methaneethorn, Duangchit Panomvana, Thaveechai Vachirayonstien
BACKGROUND: Therapeutic drug monitoring is essential for both phenytoin and phenobarbital therapy given their narrow therapeutic indexes. Nevertheless, the measurement of either phenytoin or phenobarbital concentrations might not be available in some rural hospitals. Information assisting individualized phenytoin and phenobarbital combination therapy is important. This study's objective was to determine the relationship between the maximum rate of metabolism of phenytoin (Vmax) and phenobarbital clearance (CLPB), which can serve as a guide to individualized drug therapy...
September 26, 2017: Drug Metabolism and Personalized Therapy
Nancy Hakooz, Yazun Bashir Jarrar, Malik Zihlif, Amer Imraish, Saja Hamed, Tawfiq Arafat
BACKGROUND: Human response to the antidiabetic metformin is influenced by some factors, such as genetic variants in the SLC22A genes. This study aimed to determine the frequency of main SLC22A1 and SLC22A3 genetic variants and their influence on metformin pharmacokinetics among healthy unrelated Arab Jordanians. PATIENTS AND METHODS: The SLC22A1 and SLC22A3 genes were genotyped by DNA sequencing of exons 1, 3, 7, and 9 in the SLC22A1 gene and exons 6, 7, and 9 in the SLC22A3 gene...
September 26, 2017: Drug Metabolism and Personalized Therapy
Raúl H Morales-Borges
Methylenetetrahydrofolate reductase (MTHFR) mutations have been linked to many diseases. Evidence has been provided to prove that we need to perform pharmacogenetic studies regarding the prevalence of MTHFR mutations and diseases, risks, and the impact on folate requirement in general, but little has been published about Puerto Ricans. A multi center cross-sectional retrospective review study or a prospective pharmacogenetic study of valid genotypes and phenotypes of MTHFR mutations within the different populations of Puerto Ricans and Hispanics are recommended, because differences within them and within the general population are expected...
September 26, 2017: Drug Metabolism and Personalized Therapy
Henrik Berg Rasmussen, Majbritt Busk Madsen, Yassine Kamal Lyauk, Peter Riis Hansen, Timothy Hughes
The carboxylesterase 1 gene (CES1) encodes a hydrolase implicated in the metabolism of commonly used drugs. CES1A2, a hybrid of CES1 and a CES1-like pseudogene, has a promoter that is weak in most individuals. However, some individuals harbor a promoter haplotype of this gene with two overlapping Sp1 sites that confer significantly increased transcription potentially leading to rapid drug metabolism. This CES1A2 haplotype has previously been reported to be common among Asians. Using polymerase chain reaction followed by sequencing, the present study examined variation in the promoter and 5' untranslated region of CES1A2 in 120 Han Chinese and 120 Japanese people enrolled in the 1000 Genomes Project...
September 26, 2017: Drug Metabolism and Personalized Therapy
Dmitry A Sychev, Mikhail S Zastrozhin, Igor I Miroshnichenko, Natalia V Baymeeva, Valery V Smirnov, Elena A Grishina, Kristina A Ryzhikova, Karin B Mirzaev, Dmitry D Markov, Valentin Y Skryabin, Nataliya E Snalina, Polina G Nosikova, Ludmila M Savchenko, Evgeny A Bryun
BACKGROUND: Haloperidol is used for the treatment of alcohol use disorders in patients with signs of alcohol-related psychosis. Haloperidol therapy poses a high risk of adverse drug reactions (ADR). Contradictory data, which include the effects of genetic polymorphisms in genes encoding the elements of haloperidol biotransformation system on haloperidol metabolism rate and plasma drug concentration ratio, are described in patients with different genotypes. The primary objective of this study was to investigate the effects of CYP2D6 and CYP3A5 genetic polymorphisms on haloperidol equilibrium concentration in patients with alcohol use disorder...
September 26, 2017: Drug Metabolism and Personalized Therapy
Marek Dziadosz, Michael Klintschar, Jörg Teske
BACKGROUND: As imatinib gained a lot of attention in the field of medicine, appropriate methods are needed for drug analysis. LC-MS/MS combined with complex sample preparation and column enrichment is usually the method of choice when high sensitivity is necessary. The application of LC-MS3 in imatinib quantification has not been discussed in the literature. METHODS: An LC-MS3 imatinib quantification method was developed and validated in human serum. The sample preparation was based on the liquid-liquid extraction of 50 μL human serum...
September 26, 2017: Drug Metabolism and Personalized Therapy
Felicia Stefania Falvella, Elena Ricci, Stefania Cheli, Chiara Resnati, Valeria Cozzi, Dario Cattaneo, Cristina Gervasoni, Emilio Clementi, Massimo Galli, Agostino Riva
No abstract text is available yet for this article.
May 24, 2017: Drug Metabolism and Personalized Therapy
Erika Y Tamashiro, Claudia R Felipe, Fabiana D V Genvigir, Alice C Rodrigues, Antony B Campos, Rosario D C Hirata, Helio Tedesco-Silva, Jose O Medina-Pestana
BACKGROUND: Polymorphisms in genes encoding for drug-metabolizing enzymes and drug transporters are among multiple factors that modulate the pharmacokinetic variability of tacrolimus (TAC) and sirolimus (SRL). This study aimed to evaluate the influence of single nucleotide polymorphisms (SNPs) on TAC and SRL dose-adjusted concentrations (C0/D) in stable kidney transplant recipients. METHODS: This is an exploratory and prospective study, which includes 46 stable kidney transplant recipients...
May 24, 2017: Drug Metabolism and Personalized Therapy
Dmitriy Alexeyevich Sychev, Aleksandr Vladimirovich Rozhkov, Anna Viktorovna Ananichuk, Ruslan Evgenyevich Kazakov
BACKGROUND: Acenocoumarol dose is normally determined via step-by-step adjustment process based on International Normalized Ratio (INR) measurements. During this time, the risk of adverse reactions is especially high. Several genotype-based acenocoumarol dosing algorithms have been created to predict ideal doses at the start of anticoagulant therapy. METHODS: Nine dosing algorithms were selected through a literature search. These were evaluated using a cohort of 63 patients with atrial fibrillation receiving acenocoumarol therapy...
May 24, 2017: Drug Metabolism and Personalized Therapy
Sophie Visvikis-Siest, Alex-Ander Aldasoro Arguinano, Maria Stathopoulou, Ting Xie, Alexandros Petrelis, Georges Weryha, Philippe Froguel, Peter Meier-Abt, Urs A Meyer, Vid Mlakar, Marc Ansari, Andreas Papassotiropoulos, Georges Dedoussis, Baishen Pan, Roland P Bühlmann, Mario Noyer-Weidner, Pierre-Yves Dietrich, Ron Van Schaik, Federico Innocenti, Winfried März, Lynn M Bekris, Panos Deloukas
No abstract text is available yet for this article.
May 24, 2017: Drug Metabolism and Personalized Therapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"